Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Czap Research And Development LLC has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows a spread of prosecution activity across different technical and administrative groups within the office.
David H Kruse is the busiest examiner for the company, with 1 pending office action currently assigned. This is one of the 2 total pending actions for the portfolio. The involvement of 2 distinct examiners and 2 distinct art units indicates that the company's filings in Biotechnology & Pharmaceuticals are being reviewed in different contexts. This requires managing multiple examiner relationships and technical classifications simultaneously.
The 2 pending office actions represent the current workload for Czap Research And Development LLC. Since David H Kruse is handling 1 of these, the other action is managed by the second of the 2 distinct examiners in a different art unit. This split suggests that the company's prosecution is not consolidated under a single individual or technical group. Practitioners should be prepared for diverse examiner feedback across these 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRUSE, DAVID H | 1 | 81.4% | +9.6% |
| TIEN, LUCY MINYU | 1 | 59.1% | +36.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18294821 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | KRUSE, DAVID H | 16d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17906512 | ORAL TERPENE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | TIEN, LUCY MINYU | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18294821 | ANANDAMIDE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | KRUSE, DAVID H | 1663 | §103 | Final Rejection | 16d overdue | Pending | Feb 02, 2024 |
| 17906512 | ORAL TERPENE CYCLODEXTRIN INCLUSION COMPLEX VEHICLES | TIEN, LUCY MINYU | 1612 | §103 | Final Rejection | — | Pending | Sep 16, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCzap Research And Development LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David H Kruse has the most, with 1 of Czap Research And Development LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
